Vor Biopharma (VOR) Common Equity (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Common Equity data on file, last reported at -$150.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$150.4 million, down 327.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$150.4 million (down 327.68% YoY), and the FY2025 annual result was -$164.3 million, down 69.98% from the prior year.
• Common Equity grew to -$150.4 million in Q1 2026 per VOR's latest filing, from -$164.3 million in the prior quarter.
• Over five years, Common Equity peaked at $250.6 million in Q4 2022 and troughed at -$2.2 billion in Q3 2025.
• A 5-year average of -$132.0 million and a median of $123.0 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity grew 18.39% in 2023, then tumbled 3150.49% in 2025.
• A 5-year view of Common Equity shows it stood at $250.6 million in 2022, then tumbled by 39.86% to $150.7 million in 2023, then tumbled by 164.13% to -$96.7 million in 2024, then plunged by 69.98% to -$164.3 million in 2025, then climbed by 8.45% to -$150.4 million in 2026.
• Business Quant data shows VOR's Common Equity at -$150.4 million in Q1 2026, -$164.3 million in Q4 2025, and -$2.2 billion in Q3 2025.